<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialSourcesOutput xmlns:ns2="local"><Sources><Source id="2149010" type="PR">Data at AAN Demonstrate Biogen's Leadership and Commitment to Innovation in MS</Source><Source id="1900906" type="PR">多発性硬化症治療薬「テクフィデラカプセル」2月22日に国内で発売</Source><Source id="1887169" type="PR">多発性硬化症治療薬「テクフィデラ®カプセル」製造販売承認取得</Source><Source id="1752771" type="PR">TECFIDERA Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness</Source><Source id="1701253" type="PR">New Data Show Strong, Sustained Effects of TECFIDERA (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients</Source><Source id="1666356" type="PR">Quebec Government to Cover TECFIDERA as a First-Line Oral Treatment for Multiple Sclerosis - Important Step for those Living with MS in Quebec</Source><Source id="1652494" type="PR">TECFIDERA (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients</Source><Source id="1572830" type="PR">British Columbia to Reimburse TECFIDERA™, a First-Line Oral Treatment for Multiple Sclerosis</Source><Source id="1526145" type="PR">Health Canada Approves New Strength For TECFIDERA, A First-Line Oral Treatment For Multiple SclerosisTECFIDERA now available as 240 mg delayed-release capsules</Source><Source id="1484351" type="PR">New TECFIDERA (Dimethyl Fumarate) Data Show Sustained Efficacy and Long-Term Safety in a Broad Range of Multiple Sclerosis Patients</Source><Source id="1394883" type="PR">CHMP Issues Positive Opinion for TECFIDERA (Dimethyl Fumarate) as a First-Line Treatment for Multiple Sclerosis in the European Union</Source><Source id="1330987" type="PR">New Data from Phase 3 Studies Provide Additional Evidence Supporting Treatment Effect for Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis</Source><Source id="1324824" type="PR">The New England Journal of Medicine Publishes Pivotal Data Demonstrating Efficacy and Safety of Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis</Source><Source id="1283161" type="PR">Positive Results from Phase 3 CONFIRM Clinical Trial Show Efficacy and Safety of Oral BG-12 in Multiple Sclerosis</Source><Source id="1233641" type="PR">Biogen Idec Announces Positive Top-Line Results from Second Phase 3 Trial Investigating Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis</Source><Source id="2001166" type="SERIAL">Efficacy and safety of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis in prior interferon users: an integrated analysis of define and confirm</Source><Source id="1930066" type="SERIAL">Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase iii define and confirm studies</Source><Source id="1904072" type="SERIAL">Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis</Source><Source id="1870370" type="SERIAL">Multiple sclerosis: Dimethyl fumarate is coming of age</Source><Source id="1677695" type="SERIAL">Differential recovery from relapse between treatment groups in the CONFIRM study of delayed-release dimethyl fumarate</Source><Source id="1677398" type="SERIAL">Effect of delayed-release dimethyl fumarate on total disability burden in relapsing-remitting multiple sclerosis: area under the curve analysis of changes from baseline in EDSS scores</Source><Source id="1673461" type="SERIAL">Five-year follow-up of delayed-release dimethyl fumarate in rrms: integrated clinical efficacy data from the define, confirm, and endorse studies</Source><Source id="1673447" type="SERIAL">Lymphocyte count reductions with delayed-release dimethyl fumarate: integrated analysis of the phase 2, phase 3, and extension studies</Source><Source id="1673159" type="SERIAL">Efficacy of delayed-release dimethyl fumarate for rrms in prior interferon users in the define and confirm studies</Source><Source id="1673137" type="SERIAL">Differential recovery from relapse between treatment groups in the confirm study of delayed-release dimethyl fumarate</Source><Source id="1647438" type="SERIAL">Effects of delayed-release dimethyl fumarate on mri measures in the phase 3 confirm study</Source><Source id="1584091" type="SERIAL">Delayed-release dimethyl fumarate and relapses requiring intravenous steroid use and ms-related hospitalizations: integrated analysis of the phase 3 define and confirm studies</Source><Source id="1583573" type="SERIAL">Lymphocyte count reductions in relapsing-remitting multiple sclerosis (rrms) patients treated with delayed-release dimethyl fumarate: integrated analysis of the placebo-controlled studies</Source><Source id="1583555" type="SERIAL">4-year follow-up of delayed-release dimethyl fumarate treatment in relapsing-remitting multiple sclerosis (rrms): integrated clinical efficacy data from define, confirm, and the endorse extension study</Source><Source id="1558313" type="SERIAL">Effects of bg-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the confirm study</Source><Source id="1557016" type="SERIAL">Three-year follow-up of oral bg-12 (dimethyl fumarate) treatment in relapsing remitting multiple sclerosis (rrms): integrated clinical efficacy data from the define, confirm, and endorse studies</Source><Source id="1552400" type="SERIAL">Effect of bg-12 (dimethyl fumarate) in newly diagnosed relapsing remitting multiple sclerosis (rrms) patients from the define and confirm studies</Source><Source id="1550668" type="SERIAL">Interim analysis of quality of life in patients with relapsing remitting multiple sclerosis treated with bg-12 (dimethyl fumarate) in the endorse study</Source><Source id="1350130" type="SERIAL">Placebo-controlled phase 3 study of oral bg-12 or glatiramer in multiple sclerosis</Source><Source id="1324914" type="SERIAL">Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis</Source><Source id="1284787" type="CONFERENCE">American Academy of Neurology - 64th Annual Meeting (Part IV) - OVERNIGHT REPORT, New Orleans, LA, USA</Source><Source id="1283539" type="CONFERENCE">American Academy of Neurology - 64th Annual Meeting (Part II) - OVERNIGHT REPORT, New Orleans, LA, USA</Source><Source id="2145576" type="OTHER">Peginterferon beta-1a every 2 weeks demonstrated better outcomes than glatiramer acetate once daily in patients with relapsing-remitting multiple sclerosis (RRMS): propensity score matching (PSM) of phase III data from ADVANCE and CONFIRM</Source><Source id="2145567" type="OTHER">Effects of Dimethyl Fumarate on Brain Volume Change in Relapsing-remitting Multiple Sclerosis: a Pooled Analysis of the Phase 3 DEFINE and CONFIRM Studies</Source><Source id="2084969" type="OTHER">Peginterferon beta-1a every 2 weeks demonstrated better clinical outcomes than glatiramer acetate once-daily in patients with RRMS: propensity score matching of phase 3 data from ADVANCE and CONFIRM</Source><Source id="2029380" type="OTHER">Delayed-release Dimethyl Fumarate Demonstrates Long-term, Sustained Efficacy in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis followed for at least Eight-Years</Source><Source id="2026184" type="OTHER">Lymphocyte Decline and Reconstitution After Discontinuation in Patients With Severe, Prolonged Lymphopenia Treated With Delayed-Release Dimethyl Fumarate</Source><Source id="2026079" type="OTHER">Propensity Score Matched Comparative Effectiveness Analysis of Dimethyl Fumarate Relative to Interferon, Glatiramer Acetate, or Teriflunomide Treated RRMS Outpatients in the German NeuroTransData Registry</Source><Source id="2024645" type="OTHER">NDA#204063: FDA Medical Review</Source><Source id="1975633" type="OTHER">Lymphocyte decline and reconstitution after discontinuation in patients with severe, prolonged lymphopenia treated with delayed-release dimethyl fumarate</Source><Source id="1920071" type="OTHER">Efficacy of Delayed-release Dimethyl Fumarate at Seven-Year Follow-up in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: Integrated Analysis of DEFINE, CONFIRM and ENDORSE</Source><Source id="1920036" type="OTHER">Absolute Lymphocyte Count in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Delayed-release Dimethyl Fumarate: Considerations for Patient Management</Source><Source id="1796904" type="OTHER">Absolute lymphocyte count and lymphocyte subset profiles during long-term treatment with delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis</Source><Source id="1796827" type="OTHER">Seven-year follow-up of the efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: integrated analysis of DEFINE, CONFIRM, and ENDORSE</Source><Source id="1753471" type="OTHER">Disease-Modifying Treatment Has a Similar Effect in Pediatric Onset and Adult Onset RRMS Patients: Findings from an Integrated RRMS Adult Clinical Trial Database</Source><Source id="1753459" type="OTHER">Longer-Term Follow-Up of the Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: Integrated Analysis of DEFINE, CONFIRM, and ENDORSE</Source><Source id="1753356" type="OTHER">Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis Using a Composite Measure of Disability: Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies</Source><Source id="1701131" type="OTHER">Efficacy of delayed-release dimethyl fumarate in young adults with RRMS: an integrated analysis of DEFINE and CONFIRM</Source><Source id="1701061" type="OTHER">Efficacy and safety of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis patients with cardiovascular disease: integrated analysis of the phase 3 DEFINE and CONFIRM studies</Source><Source id="1701053" type="OTHER">Efficacy of delayed-release dimethyl fumarate vs glatiramer acetate on a novel composite outcome measure of inflammatory disease activity: post-hoc analysis of the CONFIRM study</Source><Source id="1701033" type="OTHER">Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of relapsing-remitting multiple sclerosis</Source><Source id="1700720" type="OTHER">Efficacy of delayed-release dimethyl fumarate in early multiple sclerosis: post-hoc analysis of the phase 3 DEFINE and CONFIRM studies according to baseline disability</Source><Source id="1700700" type="OTHER">Efficacy of delayed-release dimethyl fumarate in early multiple sclerosis: post-hoc analysis of the phase 3 DEFINE and CONFIRM studies according to baseline cognitive function</Source><Source id="1651825" type="OTHER">Differential Recovery from Relapse Between Treatment Groups in the CONFIRM Study of Delayed-Release Dimethyl Fumarate</Source><Source id="1651686" type="OTHER">Five-Year Follow-up of Delayed-Release Dimethyl Fumarate in RRMS: Integrated Clinical Efficacy Data from the DEFINE, CONFIRM, and ENDORSE Studies</Source><Source id="1651683" type="OTHER">Efficacy of Delayed-Release Dimethyl Fumarate in Multiple Sclerosis Patients with Moderate Disability: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies</Source><Source id="1651588" type="OTHER">Efficacy of Delayed-Release Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis (RRMS) in “Non-Responders” to Prior Treatment with Interferon Beta</Source><Source id="1598338" type="OTHER">Health-related quality of life in relapsing-remitting multiple sclerosis (RRMS): Comparison with other medical conditions and effect of delayed-release dimethyl fumarate treatment</Source><Source id="1589545" type="OTHER">Differential recovery from relapse between treatment groups in the CONFIRM study of delayed-release dimethyl fumarate</Source><Source id="1589541" type="OTHER">Long-term efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with RRMS: an integrated analysis of DEFINE, CONFIRM, and ENDORSE</Source><Source id="1589532" type="OTHER">Five-year follow-up of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: MRI outcomes from DEFINE, CONFIRM, and ENDORSE</Source><Source id="1589358" type="OTHER">Delayed-release dimethyl fumarate and disability assessed by the multiple sclerosis functional composite: integrated analysis of DEFINE and CONFIRM</Source><Source id="1589322" type="OTHER">Efficacy of delayed-release dimethyl fumarate in multiple sclerosis patients with moderate disability: An integrated analysis of the phase 3 studies</Source><Source id="1545637" type="OTHER">Effect of Delayed-Release Dimethyl Fumarate on Freedom from Measured Clinical and Neuroradiological Disease Activity in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: An Integrated Analysis of DEFINE and CONFIRM</Source><Source id="1545632" type="OTHER">Effect of Delayed-Release Dimethyl Fumarate on Health-Related Quality of Life in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients According to Prior Therapy: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies</Source><Source id="1545601" type="OTHER">Clinical Efficacy of Delayed-Release Dimethyl Fumarate in Minority Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies</Source><Source id="1545558" type="OTHER">Clinical Efficacy of Delayed-Release Dimethyl Fumarate in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients with Highly Active Disease: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies</Source><Source id="1545229" type="OTHER">Health-Related Quality of Life in US Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Delayed-Release Dimethyl Fumarate: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies</Source><Source id="1525461" type="OTHER">Relapses Requiring Intravenous Steroid Use and Multiple Sclerosis (MS)-Related Hospitalizations: An Integrated Analysis of the BG-12 (Dimethyl Fumarate) Phase 3 Studies</Source><Source id="1525457" type="OTHER">Tecfidera Approved; a First-Line Oral Multiple Sclerosis Treatment</Source><Source id="1484445" type="OTHER">Effect of BG-12 (dimethyl fumarate) in newly diagnosed relapsing remitting multiple sclerosis (RRMS) patients from the DEFINE and CONFIRM studies</Source><Source id="1484400" type="OTHER">Lymphocyte count reductions in relapsing remitting multiple sclerosis (RRMS) patients treated with oral BG-12 (dimethyl fumarate): integrated analysis of the placebo-controlled studies   </Source><Source id="1484398" type="OTHER">Efficacy of BG-12 (dimethyl fumarate) in relapsing remitting multiple sclerosis in patients from Europe: an integrated analysis of the phase 3 DEFINE and CONFIRM studies   </Source><Source id="1482330" type="OTHER">Clinical efficacy of BG-12 (dimethyl fumarate) for relapsing remitting multiple sclerosis according to prior therapy: an integrated analysis of the phase 3 DEFINE and CONFIRM studies</Source><Source id="1482321" type="OTHER">Flushing and gastrointestinal tolerability events in relapsing remitting multiple sclerosis (RRMS) patients treated with oral BG-12 dimethyl fumarate) in the phase 3 DEFINE and CONFIRM trials</Source><Source id="1482310" type="OTHER">Effect of BG-12 (dimethyl fumarate) on freedom from measured clinical and neuroradiological disease activity over time in patients with relapsing remitting multiple sclerosis: results from the phase 3 studies</Source><Source id="1406908" type="OTHER">Clinical efficacy of BG-12 (dimethyl fumarate) in relapsing-remitting multiple sclerosis (RRMS): An integrated analysis of the phase III DEFINE and CONFIRM studies</Source><Source id="1406134" type="OTHER">Effect of BG-12 (dimethyl fumarate) in subgroups of patients with relapsing-remitting multiple sclerosis: An integrated analysis of the phase III DEFINE and CONFIRM studies</Source><Source id="1396161" type="OTHER">Clinical Efficacy of BG-12 (Dimethyl Fumarate) for Relapsing–Remitting Multiple Sclerosis (RRMS) According to Prior Therapy: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies</Source><Source id="1389954" type="OTHER">BG-12 (Dimethyl Fumarate) Treatment for Relapsing–Remitting Multiple Sclerosis (RRMS) Increases the Proportion of Patients Free of Measured Clinical and Neuroradiologic Disease Activity in the Phase 3 Studies</Source><Source id="1389941" type="OTHER">Clinical Efficacy of BG-12 (Dimethyl Fumarate) in Relapsing–Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies</Source><Source id="1389940" type="OTHER">Effect of BG-12 (Dimethyl Fumarate) in Subgroups of Patients with Relapsing–Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies</Source><Source id="1389934" type="OTHER">Effects of BG-12 (Dimethyl Fumarate) on Quality of Life in Patients with Relapsing–Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies</Source><Source id="1389933" type="OTHER">Clinical and Neuroradiologic Efficacy of BG-12 (Dimethyl Fumarate) in US Patients with Relapsing–Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies</Source><Source id="1330311" type="OTHER">Effects of BG-12 on magnetic resonance imaging outcomes in relapsing–remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies</Source><Source id="1330291" type="OTHER">Clinical efficacy of BG-12 in relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies</Source><Source id="1330273" type="OTHER">Clinical effects of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies</Source><Source id="1330272" type="OTHER">Effect of BG-12 on magnetic resonance imaging activity in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study</Source><Source id="1330257" type="OTHER">Effects of BG-12 on quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study</Source><Source id="1330038" type="OTHER">Effects of BG-12 on a marker of Nrf2 pathway activation: pharmacodynamic results from the phase 3 DEFINE and CONFIRM studies</Source><Source id="1330018" type="OTHER">Relapses requiring intravenous steroid use and MS-related hospitalizations: findings from the phase 3 DEFINE and CONFIRM studies</Source><Source id="1306387" type="OTHER">Clinical outcomes with BG-12 treatment in CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis), a multicentre, randomised, placebo-controlled, phase 3 study</Source><Source id="1306377" type="OTHER">Effect of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis) study</Source><Source id="1306376" type="OTHER">Safety and tolerability of BG-12 in patients with relapsing-remitting multiple sclerosis: results from the phase 3 CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis) study</Source><Source id="1283522" type="OTHER">Safety and Tolerability of BG-12 in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Analyses From the CONFIRM Study</Source><Source id="1283457" type="OTHER">Effects of BG-12 on Magnetic Resonance Imaging (MRI) Endpoints in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Data From the Phase 3 CONFIRM Study</Source><Source id="1283420" type="OTHER">Clinical Efficacy of BG-12 in Relapsing-Remitting Multiple Sclerosis (RRMS): Data from the Phase 3 CONFIRM Study</Source><Source id="1079336" type="CORPORATE">Biogen Idec Inc: Form 10-K for the year ended 31 December 2009</Source></Sources></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialSourcesOutput>